# Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy Subjects

> **NCT02256826** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 34 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BILR 355 BS
- **DRUG:** Ritonavir (RTV)
- **DRUG:** Kaletra®

## Key facts

- **NCT ID:** NCT02256826
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2005-06
- **Final completion:** —
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2014-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02256826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02256826, "Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02256826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*